Actionable news
All posts from Actionable news
Actionable news in AFMD: AFFIMED N.V.,

Affimed Therapeutics' (AFMD) CEO Adi Hoess on Q3 2015 Results - Earnings Call Transcript


Good day and welcome to the Affimed Third Quarter 2015 Financial Results and Corporate Update Conference Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Adi Hoess. Please go ahead.

Adi Hoess - CEO

Thank you very much. I'd like to welcome you to our investor and analyst call on the Q3 financial results. Before I start the corporate update and comment on the financial results, please note that this call and the Q&A session contain forward-looking statements, including statements regarding our future financial condition, business strategy and our plans and objectives for future operations. These statements represent our beliefs and assumptions only as of the date of this discussion.

Slide 3. Our mission is to transforming immuno-oncology using next generation immune cell engagement. We have an unencumbered clinical and preclinical stage pipeline based on bispecific and trispecific TandAb antibodies. We are applying our platforms to two distinct type of immune cells namely natural killer cells, or NK-Cells, and T-Cells. Our...